Why can't we find a new treatment for SLE?
- 30 June 2009
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 32 (3-4), 223-230
- https://doi.org/10.1016/j.jaut.2009.02.006
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Research & Therapy, 2008
- A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5Human Molecular Genetics, 2008
- Pathogenic role of antiphospholipid antibodiesLupus, 2008
- Translating co-stimulation blockade into clinical practiceArthritis Research & Therapy, 2008
- British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusArthritis & Rheumatism, 2007
- Deficiency of the type I interferon receptor protects mice from experimental lupusArthritis & Rheumatism, 2007
- TNFα blockade in human diseases: An overview of efficacy and safetyClinical Immunology, 2007
- STAT4and the Risk of Rheumatoid Arthritis and Systemic Lupus ErythematosusNew England Journal of Medicine, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992